Colorectal cancer (CRC) is the second most common cause of cancer-related death in the US. [8] CRC's lifetime prevalence equals 4.7% and 4.4% for men and women respectively, whereas the 5- and 10-year survival rate is 65% and 58% respectively. An array of novel methods and approaches have been described over the last years based on our increasing knowledge of the molecular events that contribute to carcinogenesis and tumor proliferation, however the go-to method for CRC's treatment remains surgical excision along with chemotherapy (adjuvant or neoadjuvant) and radiation therapy. [9] The aforementioned therapeutic approaches suffer from one or more of the following: nonspecific targeting of cancer cells, insufficient penetration to the target tissue and inadequate cytotoxicity, all of which are associated with increased mortality and decreased quality of life. [10]